Status:
COMPLETED
Oliceridine Dose for Tracheal Intubation Hemodynamic Elevation: Up-and-Down Trial
Lead Sponsor:
Shiyou Wei
Conditions:
Oliceridine
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
This is a clinical trial using an up-and-down sequential design, aiming to investigate the median effective dose (ED50) and 95% effective dose (ED95) of oliceridine for inhibiting hyperdynamic respons...
Detailed Description
1. Study Objectives To determine the ED50 and ED95 of oliceridine in inhibiting tracheal intubation-induced hyperdynamic responses (e.g., increased blood pressure and heart rate) during general anesth...
Eligibility Criteria
Inclusion
- Elective surgery requiring general anesthesia with tracheal intubation
- Age ≥ 18 years
- American Society of Anesthesiologists (ASA) physical status I-III
- BMI\<25
Exclusion
- At rest in the operating room, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 110 mmHg or heart rate ≥ 110 bpm
- Preoperative long-term use of analgesic or sedative medications
- Pregnancy, breastfeeding, known or planned pregnancy
- Known allergy or hypersensitivity to oliceridine or any study medication components
- History of psychiatric illness or inability to communicate effectively
Key Trial Info
Start Date :
September 4 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 11 2025
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT07154979
Start Date
September 4 2025
End Date
September 11 2025
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianmen First People's Hospital
Tianmen, Hubei, China, 431700